Tinnitus and subjective hearing loss, the major symptoms of salicylate ototoxicity, are generally thought to become apparent with increasing salicylate dosage and serum salicylate concentration.' 2 As salicylate dosages required to produce a non-toxic therapeutic serum concentration (generally regarded as 1 1-2 2 mmol/l) are highly variable, clinical monitoring is often desirable. [1] [2] [3] [4] [5] Although ototoxicity has been used for this purpose, we previously reported that tinnitus and subjective hearing loss are too nonspecific to be a reliable clinical tool for adjusting salicylate treatment. 6 Patients with rheumatoid arthritis receiving salicylates had no more symptoms of ototoxicity than did a healthy control group not taking the drug, and in the patients with rheumatoid arthritis symptoms often occurred with serum salicylate concentrations less than 14 mmol/l.
To define further the sensitivity and specificity of tinnitus and subjective hearing loss for therapeutic or 
Discussion
This study considers the specificity and sensitivity of tinnitus and (to a lesser degree) subjective hearing loss as reliable indicators of serum salicylate concentration. In our experience tinnitus was reported only slightly more often by patients taking regular salicylates than by healthy and rheumatic disease control groups not taking these drugs. Furthermore, most of our patients volunteering the symptom of tinnitus while taking salicylates had drug blood concentrations less than 1-3 mmol/l and most of these patients were unable to tolerate dose adjustments into the therapeutic range. Therefore not only does reported ototoxicity lack specificity for toxic serum salicylate concentrations it even lacks specificity for therapeutic concentrations. In fact, it has little specificity for salicylate consumption. Another problem, not specifically considered in this study, is the limitation imposed on salicylate use by these symptoms. It was apparent in most of the patients volunteering the symptom of tinnitus Halla, Atchison, Hardin that it was caused, or at least aggravated, by salicylates. This implies that a significant number of patients (45% in a previous report6) will be unable to tolerate an adequate salicylate dose and will have to abandon that category of non-steroidal anti-inflammatory drug in favour of another. This is especially unfortunate in light of the accumulating evidence that the nonacetylated salicylates have significantly less gastric toxicity than do other non-steroidal antiinflammatory drugs.8 9 Over half of our patients with serum salicylate concentrations greater than 2-2 mmol/l did not complain of recent tinnitus and the majority of those had noted no subjective hearing loss, even though 50% of those patients had concentrations above 2 5 mmol/l. Therefore ototoxicity is too insensitive to be a reliable indicator of salicylate toxicity. Although this study did not consider the issue of ototoxicity in subjects with serious or life threatening salicylate concentrations, a useful clinical indicator of serum salicylate concentration should sound an alarm before serious complications occur, and ototoxicity does not seem to do that.
Most of our patients with apparent ototoxicity had abnormal audiograms and most had rheumatoid arthritis. Several possibilities exist to explain the high prevalence of abnormal audiograms in these subjects. Possibly, some patients might not have stopped taking their salicylate drugs, but the abnormal audiometrics seem to be more related to increasing age or the presence of rheumatoid arthritis than to serum salicylate concentration or the presence (or absence) of tinnitus. It has been reported that hearing loss (and abnormal audiometry) increases with aging, and rheumatoid arthritis itself has been associated with hearing loss. " Our data (table 4) show that a normal audiometric response was found more often in younger rheumatoid patients with a shorter disease duration, whereas abnormal audiograms were more common and more severely abnormal in patients with a longer disease duration. In an attempt to answer some of the questions raised by this observation a continuing study is evaluating audiometric responses in a group of nonrheumatoid patients with and without salicylate treatment; audiograms are also being obtained prospectively and at regular intervals in younger patients with rheumatoid arthritis (under age 45) and in patients with disease of less than one year's duration.
One reason for the lack of sensitivity and specificity of tinnitus for salicylate ototoxicity is the increasing prevalence of tinnitus in the general population, and this prevalence is apparently independent of age.'2 '3 The National Center for Health Statistics has reported that about 32% of all adults in the United States acknowledge having tinnitus 2; and the American Tinnitus Association suggests that while almost everyone experiences tinnitus, about nine million American adults have severe unremitting symptoms.'3 The increased prevalence of the symptom has been related to our current noise polluted environment, especially the work place,'4 and may explain the lack of correlation between audiometric responses and tinnitus.
Tinnitus is a common and non-specific symptom, but it (and subjective hearing loss) is also clearly caused or aggravated by salicylates. In that case patients often become symptomatic at subtherapeutic serum salicylate concentrations, necessitating a change to another category of non-steroidal anti-inflammatory drug. As previously suggested by us and by others,2 6 15 symptomatic ototoxicity is too non-specific and too insensitive to be a clinically useful indicator of serum salicylate concentration.
